Marvel Biosciences extends private placement deadline to Sept. 14
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/20/2026
- Nasdaq climbs as chip and AI-linked stocks bounce back
- U.S. economy is "booming," JPMorgan’s Dimon says
- Musk pledges one share of SpaceX to every U.S. child
- Brent crude edges lower, even after Houthi attacks on Saudi infrastructure
- Prepare to buy the dip as U.S. stock selloff nears its end: Morgan Stanley
Tweet
Share
E-mailGet Alerts MRVL Hot Sheet
Price: $237.09 +4.06%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 0.1%
Revenue Growth %: +51.8%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 0.1%
Revenue Growth %: +51.8%
Join SI Premium – FREE
Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) has received approval from the TSX Venture Exchange to extend the closing deadline of its previously announced private placement.
The deadline for the Calgary-based company to file its final closing materials with the TSXV has been extended from August 31, 2026 to September 14, 2026. All other terms and conditions of the offering remain unchanged, according to a press release statement.
You May Also Be Interested In
- U.S. to announce certification of Boeing 737 Max 10 on Tuesday - Reuters
- 3M issues warrant to Amazon in $6B data center product deal
- Wintrust Financial (WTFC) Tops Q3 EPS by 6c
Create E-mail Alert Related Categories
Equity OfferingsRelated Entities
Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
